Cellid is at the forefront of developing innovative immunotherapeutic vaccines and infectious disease prevention vaccines, particularly focusing on cancer treatment and COVID-19. Their flagship technology, CeliVax, utilizes a unique approach by employing the patient's own B cells and monocytes as antigen-presenting cells. This method allows for the effective presentation of cancer antigens, which is crucial for eliciting a robust immune response. The CeliVax platform is designed to be applicable across various cancers, leveraging the identification of cancer antigens and the use of immune adjuvants to enhance the immune response.

In addition to their COVID-19 vaccine, AdCLD-CoV19-1 OMI, which has completed clinical trials, Cellid is also advancing several cancer vaccines, including BVAC-C, BVAC-B, and BVAC-P. These vaccines target specific cancer types, such as cervical cancer and gastric cancer, by using recombinant genes associated with cancer antigens. The company is committed to addressing unmet medical needs in oncology through its diverse pipeline, which includes ongoing clinical trials to evaluate the safety and efficacy of these vaccines. Overall, Cellid aims to redefine cancer immunotherapy and infectious disease prevention through its proprietary technologies and innovative approaches.

South Korea

Our company is an anti-cancer immunotherapy and infectious disease prevention vaccine development company that started from the laboratory of the College of Pharmacy at Seoul National University on December 11, 2006. We have developed a total of 5 types of BVAC pipeline, a personalized anti-cancer immunotherapy vaccine based on our own original technology, CeliVax, and COVID-19 vaccines. A vaccine to prevent -19 is being developed.

Cancer

Digestive System Diseases

Infectious Diseases

Kidney Diseases

Urogenital Diseases

Cellid

Anal cancer

Cervical cancer

Head and neck cancer

Human Papillomavirus

BVAC-C

Biologics

Vaccines

Breast cancer

Ovarian cancer

Stomach Cancer

BVAC-B

Glioblastoma

Prostate cancer

Renal cell carcinoma

BVAC-P

Melanoma

BVAC-M

BVAC-Neo (Personalized Anticancer vaccine)

Antibody Drug Conjugates

Therapeutic

Cellid

Company Details